The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pretreatment levels of absolute and relative eosinophil count to improve overall survival (OS) in patients with metastatic melanoma under treatment with ipilimumab, an anti CTLA-4 antibody.
Katja Schindler
Honoraria - Bristol-Myers Squibb
Kaan Harmankaya
Honoraria - Bristol-Myers Squibb
Michael Andrew Postow
Consultant or Advisory Role - Bristol-Myers Squibb (U)
Sophie Frantal
No relevant relationships to disclose
Danielle Bello
No relevant relationships to disclose
Charlotte Eielson Ariyan
Consultant or Advisory Role - Bristol-Myers Squibb
Olivier Alain Michielin
No relevant relationships to disclose
Christoph Hoeller
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Hubert Pehamberger
Consultant or Advisory Role - Bristol-Myers Squibb
Jedd D. Wolchok
Consultant or Advisory Role - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb